Other
Chronic GVHD
0
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
Chronic GVHD is an early-stage landscape with 0 programs across 1 company. The most active players are Johnson & Johnson.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
11
clinical trials
Completed6 · 55%
Terminated4 · 36%
Not yet recruiting1 · 9%
Clinical Trials
Trial Activity
11 trials
Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
Not yet recruiting·—·Phase 1·NCT06991361·21 enrolled
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD
Completed·—·Phase 1·NCT01911039·14 enrolled
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
Completed·—·Phase 1·NCT02318082·21 enrolled
Campath in Chronic GVHD
Completed·—·Phase 1·NCT00495755·13 enrolled
Rituximab for Prevention of Chronic GVHD
Completed·—·Phase 1/2·NCT00379587·65 enrolled
Multiple Donor Treg DLI for Severe Refractory Chronic GVHD
Completed·—·Phase 1/2·NCT02749084·18 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)